Overview
Dehydrated hereditary stomatocytosis (DHS), also known as hereditary xerocytosis or desiccytosis, is a rare inherited red blood cell membrane disorder characterized by increased red blood cell permeability to cations, leading to a net loss of intracellular potassium and water. This results in dehydrated, dense erythrocytes that are prone to premature destruction (hemolysis). The condition primarily affects the hematologic system, though secondary complications can involve the liver and spleen. DHS is the most common form of the hereditary stomatocytosis syndromes and is most frequently caused by mutations in the PIEZO1 gene, which encodes a mechanically activated ion channel, or less commonly in the KCNN4 gene. Key clinical features include mild to moderate hemolytic anemia, jaundice (particularly during the neonatal period), reticulocytosis, elevated mean corpuscular hemoglobin concentration (MCHC), and splenomegaly. Some patients may present with perinatal edema or hydrops fetalis. The severity of symptoms is highly variable, even within the same family, and some individuals may be nearly asymptomatic. A characteristic finding on blood smear is the presence of stomatocytes and target cells, though stomatocytes may be few in number. Patients are at increased risk of iron overload, which can occur even without transfusion therapy, and pseudohyperkalemia (falsely elevated potassium levels in vitro) is a recognized laboratory artifact. Treatment is primarily supportive. Folic acid supplementation is commonly recommended to support red blood cell production. Splenectomy is generally contraindicated in DHS because it does not significantly improve anemia and is associated with a markedly increased risk of thromboembolic complications, including portal vein thrombosis and pulmonary embolism. Monitoring and management of iron overload with chelation therapy may be necessary. Blood transfusions are occasionally required during hemolytic crises or severe anemia. Neonatal cases with hydrops fetalis may require intrauterine or postnatal transfusions.
Also known as:
Clinical phenotype terms— hover any for plain English:
Autosomal dominant
Passed on from just one parent; each child has about a 50% chance of inheriting it
Variable
Can begin at different ages, from infancy through adulthood
FDA & Trial Timeline
1 eventCentre Hospitalier Universitaire, Amiens — NA
Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
Treatments
No FDA-approved treatments are currently listed for Dehydrated hereditary stomatocytosis.
1 clinical trialare actively recruiting — trials can provide access to cutting-edge therapies.
View clinical trials →Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to Dehydrated hereditary stomatocytosis.
Community
No community posts yet. Be the first to share your experience with Dehydrated hereditary stomatocytosis.
Start the conversation →Latest news about Dehydrated hereditary stomatocytosis
Disease timeline:
New recruiting trial: The Study of the Phenotype of Hereditary Xerocytosis
A new clinical trial is recruiting patients for Dehydrated hereditary stomatocytosis
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Common questions about Dehydrated hereditary stomatocytosis
What is Dehydrated hereditary stomatocytosis?
Dehydrated hereditary stomatocytosis (DHS), also known as hereditary xerocytosis or desiccytosis, is a rare inherited red blood cell membrane disorder characterized by increased red blood cell permeability to cations, leading to a net loss of intracellular potassium and water. This results in dehydrated, dense erythrocytes that are prone to premature destruction (hemolysis). The condition primarily affects the hematologic system, though secondary complications can involve the liver and spleen. DHS is the most common form of the hereditary stomatocytosis syndromes and is most frequently caused
How is Dehydrated hereditary stomatocytosis inherited?
Dehydrated hereditary stomatocytosis follows a autosomal dominant inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.
Are there clinical trials for Dehydrated hereditary stomatocytosis?
Yes — 1 recruiting clinical trial is currently listed for Dehydrated hereditary stomatocytosis on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.
Which specialists treat Dehydrated hereditary stomatocytosis?
16 specialists and care centers treating Dehydrated hereditary stomatocytosis are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.